May 2026
📣 VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in Switzerland
Benchmark revenue and EBITDA valuation multiples for public comps like
Roche, Novartis, Lonza Group, Sandoz and Bachem.
 | Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales. | $52 | +27% | $330B | $353B | — | — | ||
| Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue. | $153 | +27% | $291B | $332B | 5.9x | 14.4x | ||
| Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations. | $630 | -13% | $44B | $49B | 5.8x | 18.2x | ||
| Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz’s total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe’s first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline. | $82 | +55% | $36B | $40B | 3.6x | 16.4x | ||
| Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and USA. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. | $100 | +52% | $8B | $7B | 8.3x | 27.0x | ||
| Dottikon ES Holding AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients for the chemical and pharmaceutical industry. | $464 | +32% | $6B | $6B | 12.8x | 34.2x | ||
| Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. | $50 | +39% | $5B | $3B | 912.5x | (5.2x) | ||
| BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island. | $56 | -- | $3B | $3B | 4.1x | — | ||
| Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33. | $124 | +70% | $2B | $2B | — | — | ||
| Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others. | $100 | -- | $2B | $2B | 13.0x | 112.9x | ||
| Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland. | $5 | +152% | $1B | $3B | 10.3x | (50.1x) | ||
| MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. | $18 | -53% | $1B | $1B | — | (4.9x) | ||
| Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries. | $68 | +18% | $843M | $753M | 2.5x | 11.5x | ||
| Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives the majority of its revenue from the European Union. | $20 | +20% | $290M | $324M | 3.3x | (8.0x) | ||
| AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others. | $3 | +66% | $288M | $199M | 43.5x | (2.3x) | ||
| BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. | $35 | -24% | $202M | $124M | 31.3x | (4.8x) | ||
| Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. | $4 | -1% | $151M | $55M | — | (0.8x) | ||
| Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc. | $29 | +98% | $150M | $146M | 10.6x | (101.6x) | ||
| MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company's neurotherapeutic products have been clinically evaluated and reported outcomes related to healthcare utilization and costs across conditions including stroke, Parkinson's disease, and age-related neurological risk. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases. | $1 | -- | $87M | $77M | 13.4x | (7.5x) | ||
| Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products. | $0 | -20% | $9M | $7M | 185.5x | (0.8x) | ||
| GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors
driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic
candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W
family (W-ENV). | -- | -- | $1M | $15M | — | — | ||
| Median | $51 | +27% | $1B | $2B | 10.5x | (0.8x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.